TICKERNERD
Menu
OPRXOPRXHealthcare · Health Information Services

OPRX Stock Forecast: OptimizeRx Corp. Price Predictions for 2026-2027

Last close, 24 Sept 2026
$7.89
+3.82% on the day

The 6 Wall Street analysts covering OptimizeRx Corp. hold a median 12-month price target of $11 — +39.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 23 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$143.2M
Ticker Nerd rank
82 / 100
Median analyst target
$11
Analysts covering
6
Revenue$20.5M−29.8% y/y
Operating income−$88K
Net income−$703K
Free cash flow$8.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.0%
1M
+3.1%
YTD
−35.6%
1Y
−57.1%
From 52W high
−63.6%
From 52W low
+73.8%
$5
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OPRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OptimizeRx Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
90
Accruals
89
Value
85
Issuance
84
Size
72
Growth
69
Revisions
43
Volatility
22
Momentum
13

Quality (90): The business earns solid, repeatable profits on what it owns.

Momentum (13): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OPRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OPRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26OPRXHigh $18Median $11Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $10Median $11High $18

The green dot is the last close — the median target sits +39.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
14 Aug 2026CitizensMaintainsMarket Outperform$9.00 → $11
13 May 2026B. Riley SecuritiesMaintainsBuy—
13 May 2026B. Riley SecuritiesMaintainsBuy$11 → $10
13 May 2026Lake StreetMaintainsBuy—
13 May 2026Lake StreetMaintainsBuy$20 → $11
13 May 2026Stephens & Co.MaintainsEqual-Weight—
13 May 2026Stephens & Co.MaintainsEqual-Weight$10 → $7.00
13 May 2026StifelMaintainsBuy$17 → $14
13 May 2026StifelMaintainsBuy—
6 Mar 2026B. Riley SecuritiesReiteratesBuy—
6 Mar 2026Lake StreetMaintainsBuy—
6 Mar 2026Roth CapitalMaintainsBuy—
6 Mar 2026Stephens & Co.MaintainsEqual-Weight—
6 Mar 2026StifelMaintainsBuy—
17 Nov 2025Stephens & Co.MaintainsEqual-Weight—
7 Nov 2025CitizensMaintainsMarket Outperform—
10 Oct 2025JMP SecuritiesMaintainsMarket Outperform—
11 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
8 Aug 2025StifelMaintainsBuy—
9 June 2025StifelMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OPRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OPRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Sept 2026, OptimizeRx Corp. returned −57.1% against +17.3% for the S&P 500, dividends included.

OPRX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26OPRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OPRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−2.9%
Analysts raising
2
Analysts cutting
2
Fundamentals

OptimizeRx Corp. (OPRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
30.4×

Cheaper than 25% of US stocks

Price / sales
1.5×

Cheaper than 60% of US stocks

Price / book
1.1×

Cheaper than 70% of US stocks

EV / EBITDA
8.9×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
−29.8%

Higher than 9% of US stocks

Earnings growth (YoY)
−29.8%

Higher than 16% of US stocks

Gross margin
76.5%

Higher than 88% of US stocks

Operating margin
−0.4%

Higher than 32% of US stocks

Net margin
4.7%

Higher than 59% of US stocks

Returns & dividend
Return on equity
3.7%

Higher than 51% of US stocks

Return on assets
4.2%

Higher than 72% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

OptimizeRx Corp. (OPRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • OptimizeRx Corp. has a market value of $143.2M and an enterprise value of $138.5M.

  • Revenue in the twelve months to 30 June 2026: $98.7M. The latest quarter shrank 29.8% year on year.

  • Net income over the same four quarters: $4.6M, a 4.7% net margin.

  • Diluted earnings per share, trailing twelve months: $0.23.

  • Free cash flow in the twelve months to 30 June 2026: $18.5M, after $217K of capital spending.

  • Shares outstanding: 18.8M.

  • Trailing P/E: 30.4×; forward P/E: 7.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • OptimizeRx Corp. employs 132 people — $747K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Sept 2026

Data provided by Twelve Data

Peers

OPRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
OPRXOptimizeRx Corp.$143.2M
82
DHDefinitive Healthcare Corp.$144.1M
78
LFMDLifeMD, Inc.$146.8M
31
HCATHealth Catalyst, Inc.$129.4M
48
SPOKSpok Holdings, Inc.$214.2M
62
AMWLAmerican Well Corp.$218.6M
86
CCLDCareCloud, Inc.$87.5M
71

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OptimizeRx Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OPRX news & analysis

OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath

GlobeNewsWire · 22 Sept 2026positive

OptimizeRx announced an integration with OpenPath, The Trade Desk's supply path optimization solution, making its authenticated point of care inventory directly available to advertisers using The Trade Desk's demand side platform. This brings net new authenticated healthcare professional reach to The Trade Desk.

Why it matters — This expands OptimizeRx's distribution of its authenticated HCP inventory to a major programmatic advertising platform, potentially broadening its advertiser reach.

OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook

Seeking Alpha · 18 Sept 2026positive

OptimizeRx was upgraded to 'Buy' on an improved 2027 growth outlook and attractive valuation. The company reported Q2 2026 gross margin of 76.5%, marking five consecutive quarters of gains, and reaffirmed 2026 guidance of $95M–$100M revenue and $21M–$25M adjusted EBITDA.

Why it matters — For OPRX watchers, the article signals strengthening profitability through a shift to higher-margin offerings and a more favorable long-term outlook.

OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence

GlobeNewsWire · 14 Sept 2026positive

OptimizeRx has expanded its Natural Language Audience Builder to unify healthcare provider (HCP) and direct-to-consumer (DTC) audience intelligence into a single workflow. The new functionality enables DSPs and agency planners to create deterministic HCP and consumer audiences more quickly.

Why it matters — OPRX watchers would care because this product expansion strengthens OptimizeRx's audience-planning capabilities, potentially broadening its appeal to demand-side platforms and agencies.

OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference

GlobeNewsWire · 8 Sept 2026neutral

OptimizeRx Corp. announced that its management will participate in the 10th Annual Lake Street Capital Best Ideas Growth Conference on Thursday, September 10, 2026, in New York, NY. The company develops healthcare technology solutions that help life sciences companies engage healthcare professionals and patients.

Why it matters — The company's participation in a major growth conference gives OPRX watchers an opportunity to hear from management and gain exposure to the investment community.

OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor

GlobeNewsWire · 2 Sept 2026positive

OptimizeRx Corp. announced the appointment of Troy Sarich, a pharma commercialization and AI expert, as a Company advisor. The announcement was made public on September 2, 2026.

Why it matters — The addition of an advisor with expertise in pharmaceutical commercialization and AI may bring specialized insight to OptimizeRx's healthcare technology offerings.

FAQ

Frequently asked questions about OPRX stock

What is the OPRX stock price forecast for 2026-2027?

The 6 Wall Street analysts covering OptimizeRx Corp. have a median 12-month price target of $11, with estimates ranging from $10 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OPRX stock a buy right now?

Of the 6 analysts covering OptimizeRx Corp., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OptimizeRx Corp. 82 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OPRX?

As at 23 Sept 2026, OptimizeRx Corp. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (90 of 100).

Will OPRX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +39.4% from the last close, and Ticker Nerd's factor model ranks OptimizeRx Corp. 82 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OPRX stock forecast for 2030?

No analyst covering OptimizeRx Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $18 over the next 12 months.

How has OPRX stock performed over the past year?

OptimizeRx Corp. returned -57.1% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OptimizeRx Corp. do?

OptimizeRx Corporation is a healthcare technology company that helps life sciences organizations connect with healthcare professionals and patients through digital engagement tools. OptimizeRx Corporation’s current offerings include digital health messaging, electronic health record workflow solutions, financial messaging, patient education, brand messaging, and patient engagement services.

What is the latest news on OPRX?

The most recent item we track (GlobeNewsWire, 22 Sept 2026): "OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath". OptimizeRx announced an integration with OpenPath, The Trade Desk's supply path optimization solution, making its authenticated point of care inventory directly available to advertisers using The Trade Desk's demand side platform. This brings net new authenticated healthcare professional reach to The Trade Desk.

Company

About OptimizeRx Corp.

OptimizeRx Corporation is a healthcare technology company that helps life sciences organizations connect with healthcare professionals and patients through digital engagement tools. OptimizeRx Corporation’s current offerings include digital health messaging, electronic health record workflow solutions, financial messaging, patient education, brand messaging, and patient engagement services. Its platform is designed to deliver timely clinical, educational, and access-related information at the point of care, supporting communication across pharmaceutical manufacturers, providers, and patients. The company operates within the healthcare information services and digital health market, where it plays a role in improving how treatment information and support resources are shared in clinical settings. Founded in 2006 and headquartered in Waltham, Massachusetts, OptimizeRx Corporation focuses on technology-enabled solutions for the healthcare communications ecosystem.

CEO Mr. Stephen L. Silvestro · 132 employees · United States · https://www.optimizerx.com